A nested case-control study in the European Prospective Investigation into Cancer and the nutrition (EPIC)-Varese cohort found a statistically significant negative association between adiponectin (an anti-inflammatory molecule that is involved in the inhibition of IL-6 production, accompanied by induction of the anti-inflammatory cytokines IL-10 and IL-1 receptor antagonists [45]) and breast cancer risk for postmenopausal women (highest versus lowest tertile: RR 0.37, 95% CI: 0.19, 0.72), but not for premenopausal women (RR 1.11, 95% CI: 0.61, 2.03) [25]. Here, ADIPOQ is linked to breast carcinoma.